Randomised phase II screening study to be used in an TPF-chemotherapy [docetaxel + cisplatin + fluorouracil] (short induction) before TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/hypopharynx. [Randomised phase II screeningstudy to be used in a TP/TPF-chemotherapy (shortinduction) before TP/TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/ hypopharynx.]
Latest Information Update: 09 May 2022
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Laryngeal cancer
- Focus Therapeutic Use
- Acronyms DeLOS II
- 01 Oct 2018 Results published in the Annals of Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 25 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by European Clinical Trials Database record.